Ratings Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
13.54 ^USD	-2.31%		-6.49%	+17.94%

Apr. 30	Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	MT
Apr. 30	Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALVOTECH	+17.94%	3.79B	-
MODERNA, INC.	+23.37%	46.71B	B-
LONZA GROUP AG	+48.83%	41.8B	A
IQVIA HOLDINGS INC.	-0.94%	41.52B	B
CELLTRION, INC.	-5.86%	29.55B	C
ICON PUBLIC LIMITED COMPANY	+11.29%	25.78B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.92%	19.26B	B
BIO-TECHNE CORPORATION	+3.20%	12.14B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.67%	12.08B	C+
MEDPACE HOLDINGS, INC.	+30.23%	11.98B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes